eFoodSafety.com, Inc. Announces Successful Formulation of a Trans-dermal Delivery System for Citroxin Aimed at Eradicating the MRSA Virus 'Super Bug'

Scottsdale, AZ - (WORLD STOCK WIRE) - November 27, 2007 -- eFoodSafety.com, Inc. (OTCBB: EFSF) today announced that its wholly-owned subsidiary Knock-Out Technologies, Ltd. has completed the research and development phase of incorporating its clinically proven product, Citroxin, into a unique trans-dermal cream with proven efficacy in transporting bio-active components beyond the level of the skin's outer-most layer (stratus corneum).

The goal is to permit the active compounds in Citroxin to enter into systemic circulation, thereby allowing the proven health benefits of Citroxin to quickly improve numerous facets of internal health. On the back of the recent successful lab test demonstrating Citroxin's ability to eradicate MRSA (Methicillin Resistant Staphylococcus Aureus), the initial aim of Trans-dermal Citroxin will be to allow Citroxin to be delivered in an efficacious dose directly into the bloodstream. This will arm the body's defense systems to directly deal with most strains of Staph infection.

Robert Bowker, President of Knock-Out Technologies, Ltd., stated, "One of the key challenges in formulating a trans-dermal product was to create a suitable suspension of Citroxin's components, coupled with the proper vehicle used for trans-dermal delivery. Through continued innovation, we believe we have successfully achieved this objective, resulting in a novel method for introducing Citroxin into the body through a route other than oral ingestion. This achievement is extremely important and beneficial, as many people who are ill or weakened by various factors cannot swallow pills. Additionally, these people, as well as many others, have a deficient ability to properly digest and assimilate nutrients through normal digestive mechanisms. We believe that Trans-dermal Citroxin provides a solution to overcoming these obstacles."

Trans-dermal delivery is a term that relates to any topically applied drug formulations that are meant to deliver one or more active ingredients into the overall circulation. Trans-dermal systems have been formulated to afford controlled delivery of specific drugs into systemic blood supply. These systems can help avoid some typical problems associated with oral ingestion of drugs and nutrients, including destruction of active components from stomach acid, nausea or stomach upset, and reflux from swallowing difficulties. Skin is normally impermeable to most substances. However, certain systems have been designed which allow the skin's matrix to be permeated with an inactive compound that carries the active ingredient(s) through the normal barrier system. Several drugs are now in use in trans-dermal products, including anti-histamines, beta-blockers, non-steroidal anti-inflammatories, contraceptives, insulin, hormones, and anti-virals.

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The OraPhyte(TM) product which has been tested and shown to be effective at eradicating nematodes by the U.S. Department of Agriculture is currently at three major universities with outstanding Agricultural Departments undergoing crop-specific research.

The Company is the owner of Cinnergen(TM), a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism available for sale at (www.cinnergen.com) and through national retailers; and Cinnechol(TM), a multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.

The company's iBoost, Inc. subsidiary is the distributor of the Immune Boost Bar(TM), a non-dairy, no refined sugar, all-natural and comprehensive multi-nutrient product that helps fortify the body's immune system. The product contains Citroxin(TM), eFoodSafety's proprietary all natural supplement proven effective in fighting several types of harmful bacteria, and forty active compounds that assist with enhancing immunity, detoxification, cleansing, and metabolic efficiency. The Immune Boost Bar(TM) is available in three delicious flavors: chocolate, oatmeal-raisin, and orange-apple and can be purchased at www.immuneboost.com.

The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line.

Please visit the Company's website at: http://www.efoodsafety.com.

Safe Harbor Forward-Looking Statements
Statements contained in this release that are not strictly historical are "forward-looking statements." Such forward-looking statements are sometimes identified by words such as "intends," "anticipates," "believes," "expects" and "hopes." The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.



Patricia Gruden
efoodsafety.com, Inc.
7702 East Doubletree Ranch Road
Suite 300
Scottsdale, AZ 85258
USA

Phone: 415-884-0348
Fax: 480-348-3999


Source: efoodsafety.com, Inc.
Note: The following press release was submitted by: efoodsafety.com, Inc., and World Stock Wire, Inc. is not liable for the contents of this press release.